Top

Published in:

Open Access 01-09-2019 | Obesity | Article

Novel metabolic indices and incident type 2 diabetes among women and men: the Rotterdam Study

Authors: Adela Brahimaj, Fernando Rivadeneira, Taulant Muka, Eric J. G. Sijbrands, Oscar H. Franco, Abbas Dehghan, Maryam Kavousi

Published in: Diabetologia | Issue 9/2019

Abstract

Aims/hypothesis

Both visceral and truncal fat have been associated with metabolic disturbances. We aimed to investigate the associations of several novel metabolic indices, combining anthropometric and lipid measures, and dual-energy x-ray absorptiometry (DXA) measurements of body fat, with incident type 2 diabetes among women and men from the large population-based Rotterdam Study.

Methods

Cox proportional hazards models were used to investigate associations of visceral adiposity index (VAI), lipid accumulation product (LAP), the product of triacylglycerol and glucose (TyG), their formula components and DXA measures with incident type 2 diabetes. Associations were adjusted for traditional diabetes risk factors.

Results

Among 5576 women and 3988 men free of diabetes, 511 women and 388 men developed type 2 diabetes during a median follow-up of 6.5 years. In adjusted models, the three metabolic indices VAI (per 1 SD naturally log-transformed HR; 95% CI) (1.49; 1.36, 1.65 in women; 1.37; 1.22, 1.53 in men), LAP (1.35; 1.16, 1.56 in women; 1.19; 1.01, 1.42 in men) and TyG (1.73; 1.52, 1.98 in women; 1.43; 1.26, 1.62 in men), gynoid fat mass (0.63; 0.45, 0.89) and android to gynoid fat ratio (1.51; 1.16, 1.97) in women were associated with incident type 2 diabetes. BMI (1.45; 1.28, 1.65) was the strongest predictor of type 2 diabetes in men.

Conclusions/interpretation

Among women, novel combined metabolic indices were stronger risk markers for type 2 diabetes than the traditional anthropometric and laboratory measures and were comparable with DXA measures. Neither combined metabolic indices nor DXA measures were superior to traditional anthropometric and lipid measures in association with type 2 diabetes among men.

Available only for authorised users

Després J-P, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881–887

Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY (2013) Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. Diabetes Care 36(2):289–293. https://doi.org/10.2337/dc12-0198 PubMedCentralCrossRefPubMed

Neeland IJ, Turer AT, Ayers CR et al (2012) Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308(11):1150–1159. https://doi.org/10.1001/2012.jama.11132 PubMedCentralCrossRefPubMed

Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L (2000) Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 23(4):465–471. https://doi.org/10.2337/diacare.23.4.465 CrossRefPubMed

Kang SM, Yoon JW, Ahn HY et al (2011) Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS One 6(11):e27694. https://doi.org/10.1371/journal.pone.0027694 PubMedCentralCrossRefPubMed

Fu X, Song A, Zhou Y et al (2014) Association of regional body fat with metabolic risks in Chinese women. Public Health Nutr 17(10):2316–2324. https://doi.org/10.1017/S1368980013002668 CrossRefPubMed

DeNino WF, Tchernof A, Dionne IJ et al (2001) Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 24(5):925–932. https://doi.org/10.2337/diacare.24.5.925 CrossRefPubMed

Fox CS, Massaro JM, Hoffmann U et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1):39–48. https://doi.org/10.1161/CIRCULATIONAHA.106.675355

McLaughlin T, Lamendola C, Liu A, Abbasi F (2011) Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 96(11):E1756–E1760. https://doi.org/10.1210/jc.2011-0615 PubMedCentralCrossRefPubMed

10.

Preis SR, Massaro JM, Robins SJ et al (2010) Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study. Obesity (Silver Spring) 18(11):2191–2198. https://doi.org/10.1038/oby.2010.59 CrossRef

11.

Camhi SM, Bray GA, Bouchard C et al (2011) The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring) 19(2):402–408. https://doi.org/10.1038/oby.2010.248 CrossRef

12.

Shah RV, Murthy VL, Abbasi SA et al (2014) Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging 7(12):1221–1235. https://doi.org/10.1016/j.jcmg.2014.07.017 PubMedCentralCrossRefPubMed

13.

Okosun IS, Seale JP, Lyn R (2015) Commingling effect of gynoid and android fat patterns on cardiometabolic dysregulation in normal weight American adults. Nutr Diabetes 5(5):e155. https://doi.org/10.1038/nutd.2015.5 PubMedCentralCrossRefPubMed

14.

Doran DA, Mc Geever S, Collins KD, Quinn C, McElhone R, Scott M (2014) The validity of commonly used adipose tissue body composition equations relative to dual energy X-ray absorptiometry (DXA) in Gaelic Games players. Int J Sports Med 35:95–100PubMed

15.

Amato MC, Giordano C, Galia M et al (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4):920–922. https://doi.org/10.2337/dc09-1825 PubMedCentralCrossRefPubMed

16.

Wakabayashi I, Daimon T (2014) A strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. J Atheroscler Thromb 21(3):282–288. https://doi.org/10.5551/jat.20628 CrossRefPubMed

17.

Lemieux I, Pascot A, Couillard C et al (2000) Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2):179–184. https://doi.org/10.1161/01.CIR.102.2.179 CrossRefPubMed

18.

Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6(4):299–304. https://doi.org/10.1089/met.2008.0034 CrossRefPubMed

19.

Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X (2014) Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol 13(1):146. https://doi.org/10.1186/s12933-014-0146-3 PubMedCentralCrossRefPubMed

20.

Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M et al (2010) The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 95(7):3347–3351. https://doi.org/10.1210/jc.2010-0288 CrossRefPubMed

21.

Hofman A, Brusselle GG, Darwish Murad S et al (2015) The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 30(8):661–708. https://doi.org/10.1007/s10654-015-0082-x PubMedCentralCrossRefPubMed

22.

Kahn HS (2005) The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 5(1):26. https://doi.org/10.1186/1471-2261-5-26 PubMedCentralCrossRefPubMed

23.

Ikram MA, Brusselle GGO, Murad SD et al (2017) The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 32(9):807–850. https://doi.org/10.1007/s10654-017-0321-4 PubMedCentralCrossRefPubMed

24.

World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006: WHO, Geneva

25.

Ligthart S, van Herpt TT, Leening MJ et al (2016) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4(1):44–51. https://doi.org/10.1016/S2213-8587(15)00362-9 CrossRefPubMed

26.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. https://doi.org/10.1007/BF00280883 CrossRefPubMed

27.

Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326(7382):219. https://doi.org/10.1136/bmj.326.7382.219 PubMedCentralCrossRefPubMed

28.

Liu PJ, Ma F, Lou HP, Chen Y (2016) Visceral adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20-50. Ann Nutr Metab 68(4):235–243. https://doi.org/10.1159/000446121 CrossRefPubMed

29.

Vasques AC, Novaes FS, de Oliveira Mda S et al (2011) TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract 93(3):e98–e100. https://doi.org/10.1016/j.diabres.2011.05.030 CrossRefPubMed

30.

Hameed EK (2019) TyG index a promising biomarker for glycemic control in type 2 diabetes mellitus. Diabetes Metab Syndr 13(1):560–563. https://doi.org/10.1016/j.dsx.2018.11.030 CrossRefPubMed

31.

Ansari AM, Bhat KG, Dsa SS, Mahalingam S, Joseph N (2018) Study of insulin resistance in patients with β thalassemia major and validity of triglyceride glucose (TYG) index. J Pediatr Hematol Oncol 40(2):128–131. https://doi.org/10.1097/MPH.0000000000001011 CrossRefPubMed

32.

Lambrinoudaki I, Kazani MV, Armeni E et al (2018) The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women. Heart Lung Circ 27(6):716–724. https://doi.org/10.1016/j.hlc.2017.05.142 CrossRefPubMed

33.

Navarro-Gonzalez D, Sanchez-Inigo L, Fernandez-Montero A, Pastrana-Delgado J, Martinez JA (2016) TyG index change is more determinant for forecasting type 2 diabetes onset than weight gain. Medicine (Baltimore) 95(19):e3646. https://doi.org/10.1097/MD.0000000000003646 CrossRef

34.

Vieira-Ribeiro SA, Fonseca PCA, Andreoli CS et al (2019) The TyG index cutoff point and its association with body adiposity and lifestyle in children. J Pediatr 95(2):217–223. https://doi.org/10.1016/j.jped.2017.12.012 CrossRef

35.

Khan SH, Sobia F, Niazi NK, Manzoor SM, Fazal N, Ahmad F (2018) Metabolic clustering of risk factors: evaluation of triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr 10(1):74. https://doi.org/10.1186/s13098-018-0376-8 PubMedCentralCrossRefPubMed

36.

Teng MS, Wu S, Er LK, Hsu LA, Chou HH, Ko YL (2018) LIPC variants as genetic determinants of adiposity status, visceral adiposity indicators, and triglyceride-glucose (TyG) index-related parameters mediated by serum triglyceride levels. Diabetol Metab Syndr 10(1):79. https://doi.org/10.1186/s13098-018-0383-9 PubMedCentralCrossRefPubMed

37.

Navarro-Gonzalez D, Sanchez-Inigo L, Pastrana-Delgado J, Fernandez-Montero A, Martinez JA (2016) Triglyceride-glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort. Prev Med 86:99–105. https://doi.org/10.1016/j.ypmed.2016.01.022 CrossRefPubMed

38.

Er LK, Wu S, Chou HH et al (2016) Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS One 11(3):e0149731. https://doi.org/10.1371/journal.pone.0149731 PubMedCentralCrossRefPubMed

39.

Klein S, Allison DB, Heymsfield SB et al (2007) Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 85(5):1197–1202. https://doi.org/10.1093/ajcn/85.5.1197 CrossRefPubMed

40.

Sironi AM, Petz R, De Marchi D et al (2012) Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med 29(5):622–627. https://doi.org/10.1111/j.1464-5491.2011.03503.x CrossRefPubMed

41.

Liu J, Fox CS, Hickson D, Bidulescu A, Carr JJ, Taylor HA (2011) Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 31(11):2715–2722. https://doi.org/10.1161/ATVBAHA.111.234062 PubMedCentralCrossRefPubMed

42.

Britton KA, Fox CS (2011) Ectopic fat depots and cardiovascular disease. Circulation 124(24):e837–e841. https://doi.org/10.1161/CIRCULATIONAHA.111.077602 CrossRefPubMed

43.

Bays HE (2012) Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol 110(9):4B–12B. https://doi.org/10.1016/j.amjcard.2012.08.029 CrossRefPubMed

44.

Kanaya AM, Harris T, Goodpaster BH, Tylavsky F, Cummings SR (2004) Health, Aging, and Body Composition (ABC) Study: Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 27(6):1375–1380. https://doi.org/10.2337/diacare.27.6.1375 CrossRefPubMed

45.

Tanaka S, Togashi K, Rankinen T et al (2004) Sex differences in the relationships of abdominal fat to cardiovascular disease risk among normal-weight white subjects. Int J Obes Relat Metab Disord 28(2):320–323. https://doi.org/10.1038/sj.ijo.0802545 CrossRefPubMed

46.

Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113(11):1582–1588. https://doi.org/10.1172/JCI21047 PubMedCentralCrossRefPubMed

47.

Smith SR, Lovejoy JC, Greenway F et al (2001) Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 50(4):425–435. https://doi.org/10.1053/meta.2001.21693 CrossRefPubMed

48.

Direk K, Cecelja M, Astle W et al (2013) The relationship between DXA-based and anthropometric measures of visceral fat and morbidity in women. BMC Cardiovasc Disord 13(1):25. https://doi.org/10.1186/1471-2261-13-25 PubMedCentralCrossRefPubMed

49.

Snijder MB, Visser M, Dekker JM et al (2005) Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia 48(2):301–308. https://doi.org/10.1007/s00125-004-1637-7 CrossRefPubMed

50.

Hill MJ, Metcalfe D, McTernan PG (2009) Obesity and diabetes: lipids, ‘nowhere to run to’. Clin Sci (Lond) 116(2):113–123. https://doi.org/10.1042/CS20080050 CrossRef

51.

Min KB, Min JY (2015) Android and gynoid fat percentages and serum lipid levels in United States adults. Clin Endocrinol 82(3):377–387. https://doi.org/10.1111/cen.12505 CrossRef

52.

Bouchi R, Fukuda T, Takeuchi T et al (2017) Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes. BMC Obes 4(1):27. https://doi.org/10.1186/s40608-017-0163-3 PubMedCentralCrossRefPubMed

Title: Novel metabolic indices and incident type 2 diabetes among women and men: the Rotterdam Study
Authors: Adela Brahimaj
Fernando Rivadeneira
Taulant Muka
Eric J. G. Sijbrands
Oscar H. Franco
Abbas Dehghan
Maryam Kavousi
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Obesity
Type 2 Diabetes
Published in: Diabetologia / Issue 9/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-019-4921-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 9/2019

Clinical aspects of heart failure in individuals with diabetes

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

Circulating CXCR5−PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes

Myokines in metabolic homeostasis and diabetes

Biomarker panels associated with progression of renal disease in type 1 diabetes

New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage